Your browser is no longer supported. Please, upgrade your browser.
AbbVie Inc.
IndexS&P 500 P/E53.22 EPS (ttm)1.10 Insider Own0.10% Shs Outstand1.59B Perf Week-1.83%
Market Cap93.20B Forward P/E11.88 EPS next Y4.93 Insider Trans-3.22% Shs Float1.57B Perf Month-3.18%
Income1.77B PEG3.38 EPS next Q0.85 Inst Own73.00% Short Float1.24% Perf Quarter-12.15%
Sales19.96B P/S4.67 EPS this Y-57.20% Inst Trans0.27% Short Ratio1.68 Perf Half Y1.54%
Book/sh1.09 P/B53.71 EPS next Y14.13% ROA6.20% Target Price69.08 Perf Year17.53%
Cash/sh5.26 P/C11.13 EPS next 5Y15.73% ROE43.50% 52W Range44.49 - 70.23 Perf YTD-9.87%
Dividend2.04 P/FCF337.70 EPS past 5Y-17.80% ROI16.80% 52W High-16.65% Beta-
Dividend %3.48% Quick Ratio1.30 Sales past 5Y7.00% Gross Margin78.20% 52W Low31.58% ATR1.32
Employees26000 Current Ratio1.40 Sales Q/Q6.70% Oper. Margin19.20% RSI (14)47.83 Volatility1.78% 2.43%
OptionableYes Debt/Eq8.62 EPS Q/Q-172.90% Profit Margin8.90% Rel Volume1.01 Prev Close58.24
ShortableYes LT Debt/Eq6.06 EarningsApr 24 BMO Payout149.50% Avg Volume11.62M Price58.54
Recom2.40 SMA200.22% SMA50-1.64% SMA200-0.48% Volume11,795,429 Change0.52%
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Jun-24-14Reiterated Argus Buy $59 → $65
Jan-06-14Reiterated UBS Neutral $46 → $56
Oct-29-13Reiterated Argus Buy $52 → $59
Aug-12-13Initiated Argus Buy $52
May-15-13Reiterated R. F. Lafferty Buy $47.90 → $61
Apr-29-13Reiterated Barclays Equal Weight $41 → $44
Apr-15-13Reiterated Barclays Equal Weight $37 → $41
Mar-31-15 06:09PM  Market for Health Deals Is In the Pink at The Wall Street Journal
10:05AM  Could the Life Time Fitness Deal Get Competitive?
09:30AM  The Zacks Analyst Blog Highlights: Google, Johnson & Johnson, AbbVie, Yahoo and Microsoft - Press Releases
Mar-30-15 06:09PM  Biogen/AbbVie's MS Drug Zinbryta Under Review in the EU - Analyst Blog
09:06AM  Is the PharmacyclicsAbbVie Merger a Setup?
08:04AM  ABBVIE INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
08:00AM  Pain and Erectile Dysfunction Make Pfizer Biggest in Drug Ads at Bloomberg
06:15AM  Horizon to Buy Hyperion for $1.1 Billion, Gain Rare-Disease Drug at Bloomberg
Mar-28-15 07:00AM  Hyperion Could Be Next Pharma Target With Orphan Drugs: Real M&A at Bloomberg
01:05AM  The Risk-to-Reward Ratio of the PharmacyclicsAbbVie Merger
01:05AM  The PharmacyclicsAbbVie Merger: What Are the Details?
Mar-27-15 06:40PM  Cramer: 4 horsemen of biotech & semis are back at CNBC
04:06PM  Is Antitrust a Risk in the Life Time Fitness Merger?
12:06PM  Life Time Fitness: An Activity for Everyone
07:00AM  European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA (Daclizumab High-Yield Process) for Treatment of MS Business Wire
Mar-26-15 06:06PM  Transaction Basics of the Life Time Fitness Merger
Mar-25-15 07:01PM  Read This Before You Sell Gilead Sciences at Investopedia
11:10AM  4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary
10:28AM  Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Update - Analyst Blog
10:06AM  The PharmacyclicsAbbVie Merger: The Basics of Pharmacyclics
Mar-24-15 05:15PM  Google-backed aging research company Calico cuts local research deal at
05:01PM  Why All Those Testosterone Ads Constitute Disease Mongering at Forbes
12:06PM  Could the PharmacyclicsAbbVie Merger Get Competitive?
11:57AM  Edelman, iShares Launch Exponential Technologies ETF ETF Trends
11:57AM  Edeleman, iShares Launch Exponential Technologies ETF ETF Trends
09:00AM  TG Therapeutics Is A Best Idea at Forbes
12:01AM  New Alzheimer's Research Throws Cold Water on Biogen's Recent Breakthrough
Mar-23-15 04:10PM  Gilead: Buy the Pullback at
02:31PM  Gilead shares dip after warning about hepatitis C drug interaction Reuters
02:05PM  Is Antitrust a Risk in the PharmacyclicsAbbVie Merger?
01:31PM  Pharmacyclics chief to receive $3.6bn from takeover at Financial Times
10:48AM  Gilead Sciences' Hepatitis-C Warning a 'Non-Event,' 'Buy on Weakness' at
10:06AM  Rationale for the PharmacyclicsAbbVie Merger
09:04AM  Big Pharma But Not Such Big Money at Forbes
08:50AM  Cramer's stocks to watch: Amazing biotech
08:10AM  ABBVIE INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Mar-21-15 12:18AM  AbbVie And C2N Enter Into A Worldwide License Agreement For Alzheimer's Disease Therapy at noodls
Mar-20-15 07:44PM  Lightning Round: Too much competition in this at CNBC
07:26PM  Cramer Remix: Cha-ching! Time to cash in at CNBC
05:02PM  ABBVIE INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
04:27PM  Biotech bulls take charge
11:58AM  The PharmacyclicsAbbVie Merger Shareholders Could Benefit
11:06AM  Viking Global Exited Its Position in AbbVie
Mar-19-15 10:42PM  Big Pharma Needs to Get Busy in the Lab at The Wall Street Journal
06:52PM  Big Pharma Needs to Get Busy in the Lab at The Wall Street Journal
03:54PM  Celgene's Data on Crohn's Disease Candidate Published - Analyst Blog
01:40PM  Aldeyra Initiates Phase II Sjogren-Larsson Syndrome Study - Analyst Blog
08:44AM  AbbVie And C2N Enter Into A Worldwide License Agreement For Alzheimer's Disease Therapy PR Newswire
Mar-18-15 02:54PM  Biotechs Best Friend Celgene Has Alliance Strategy Put to Test at Bloomberg
10:49AM  Biotech Stock Roundup: Amgen & Regeneron Shine at ACC, Nektar Drug Disappoints - Analyst Blog
10:28AM  The Scariest Health Care Statistic of 2014
Mar-17-15 05:05PM  Understanding Johnson & Johnsons Growth Strategies
04:20PM  Pharmacyclics' Imbruvica Encourages in a Phase III Study - Analyst Blog
02:41PM  AbbVie to Buy Pharmacyclics: Biotech ETFs to Watch - ETF News And Commentary
10:52AM  Why These Could Be 2015's 10-Best Pharma Stocks at Investopedia
08:42AM  Critical Reports Mount On Hepatitis C Pill Costs at Forbes
08:23AM  AbbVie's Dermatology Leadership Showcased with HUMIRA® (adalimumab) Data at American Academy of Dermatology 2015 Annual Meeting at noodls
08:00AM  AbbVie's Dermatology Leadership Showcased with HUMIRA® (adalimumab) Data at American Academy of Dermatology 2015 Annual Meeting PR Newswire
Mar-16-15 05:08PM  Pharmacyclics cancer drug successful as combination therapy - independent panel Reuters
05:00PM  Gilead's hepatitis C drugs largely cost-effective in U.S. -study Reuters
03:42PM  FDA panel recommends unblinding study after Imbruvica shows clear benefit Reuters
02:29PM  Erin Go Bragh! American Companies See Green in Ireland at Fox Business
12:42PM  The Hottest Question in Pharma: Which Company Will Be Next To Sell? at The Wall Street Journal
08:55AM  Should Investors Buy These 4 Bad News Stocks for Big Gains? at 24/7 Wall St.
12:11AM  MoneyBeat: U.S. Catches M&A Fever at The Wall Street Journal
Mar-15-15 09:07PM  MoneyBeat: U.S. Catches M&A Fever at The Wall Street Journal
Mar-13-15 04:45PM  Bristol-Myers Seeks Daclatasvir Approval in the U.S. - Analyst Blog
04:05PM  Teachers fund exits position in Shire
Mar-12-15 05:20PM  Salix Up on Endo Proposal Outstripping Valeant Offer - Analyst Blog
09:30AM  The Zacks Analyst Blog Highlights: AbbVie, Pharmacyclics, Amgen, United Therapeutics and Regeneron - Press Releases
09:00AM  Can Chicago's Tech Community Carry Rahm Emanuel To Victory? at Forbes
07:14AM  CVS: Copycat drugs may bring price cuts of 40-50% at CNBC
Mar-11-15 06:01PM  Endo offers about $11 bln for Salix, trumping Valeant Reuters
05:58PM  Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog
03:31PM  Express Scripts Issues Report on Prescription Drug Spending - Analyst Blog
02:38PM  Jim Cramer's Trust Sells Out of AbbVie: What Wall Street's Saying at TheStreet
02:02PM  Endo Intl has offered to buy Salix Pharma -source
01:04PM  AbbVie to Present at Barclays Global Health Care Conference at noodls
01:04PM  AbbVie to Acquire Pharmacyclics, including its blockbuster product Imbruvica®, Creating an Industry Leading Hematological Oncology Franchise at noodls
09:54AM  Biotech Stock Roundup: AbbVie to Buy Pharmacyclics, FDA Approves First Biosimilar - Analyst Blog Zacks
Mar-10-15 12:49PM  Hepatitis C Meds Absorb Most Of 13% Jump In Drug Spending Investor's Business Daily
12:49PM  Drug Spending Accelerated In 2014: Express Scripts at Investor's Business Daily
12:30PM  Hepatitis C drugs drive 13% jump in medicine spending at MarketWatch
11:00AM  ETFs for the Next Biotech Takeover Targets ETF Trends
10:52AM  Prescription drug spending on the rise Yahoo Finance
08:53AM  What!?! Specialty drug spending jumps 31% at CNBC
08:26AM  Hepatitis C pills drive surge in U.S. drug costs -report Reuters
07:05AM  US specialty drug spending trends in 2015 CNBC
07:04AM  Prescription drug prices rising: Report CNBC
12:01AM  Drug Costs Grew Last Year at Fastest Rate in Decade, Report Says at Bloomberg
12:00AM  Hepatitis Pills Spark Biggest Jump In Drug Costs In A Decade at Forbes
Mar-09-15 07:00PM  Drugmaker Galapagos Evolves Into Target for AbbVie, J&J at Bloomberg
04:10PM  Bracing for Biotech Copycats, Amgen Plans Its Own Imitations Bloomberg
03:05PM  Bracing for Biotech Copycats, Amgen Plans Imitations of Its Own at Bloomberg
11:58AM  Investors Bet $100,000 Cancer Drug Prices Are Here to Stay Bloomberg
09:30AM  A Biotech ETF Right for Oncology Mergers and Acquisitions ETF Trends
Mar-06-15 11:47PM  Last Week at
05:52PM  FDA OKs First Biosimilar Drug, Knockoff Of Amgen's Neupogen Investor's Business Daily
04:21PM  Pharmacyclics Set to Be Acquired by AbbVie for $21B - Analyst Blog Zacks
02:12PM  Going the extra mile to win a £21bn deal at Financial Times
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company's products include HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, including those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants. It also provides AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and the treatment of endometriosis and central precocious puberty, as well as for the preoperative treatment of patients with anemia. In addition, the company offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, Niaspan, Simcor, and Advicor to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has strategic collaboration with Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, Alvine Pharmaceuticals, Inc., and Action Pharma A/S. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GCMar 02Sale60.3025,0001,507,500274,116Mar 03 06:10 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesMar 02Sale60.3012,314742,534106,954Mar 03 06:07 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 27Sale60.472,112127,706104,555Mar 03 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 27Sale60.512,074125,492123,860Mar 03 06:07 PM
HURWICH THOMAS A.VP, ControllerFeb 27Sale60.571,18571,77770,322Mar 03 06:06 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 17Sale58.7024114,147106,592Feb 19 05:51 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 09Option Exercise24.072,25054,1643,168Feb 11 05:28 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Option Exercise24.078,495204,501188,563Dec 22 05:22 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Sale68.008,495577,660180,068Dec 22 05:22 PM
HURWICH THOMAS A.VP, ControllerNov 24Sale67.811,500101,71763,211Nov 26 05:00 PM
HURWICH THOMAS A.VP, ControllerNov 06Option Exercise24.0710,000240,73171,448Nov 07 05:57 PM